Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interleukin-1beta promotes repair of the CNS.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Rituximab does not reset defective early B cell tolerance checkpoints.
Multiple sclerosis: pathogenesis and treatment.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Firategrast
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Dimethylfumarate Impairs Neutrophil Functions.
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Multiple sclerosis prevalence in the United States commercially insured population.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.

Pages